Eli Lilly and Company (LLY)
Eli Lilly to spend $5.3 billion to boost Zepbound, Mounjaro manufacturing
Eli Lilly & Co. said Friday that it has more than doubled its investment in a Lebanon, Ind., site to boost manufacturing capacity for its popular weight-loss drug Zepbound and diabetes treatment Mounjaro.
Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars
Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
Eli Lilly said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to expand the supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro and other medicines in its pipeline. Demand for Zepbound and Mounjaro has far outpaced supply over the last year, spurring shortages in the U.S. and forcing the pharmaceutical giant to invest heavily to scale up its manufacturing.
Eli Lilly to Spend $5.3 Billion to Make More Mounjaro, Zepbound
The outlay to expand an Indiana production site, combined with a previous $3.7 billion commitment, is the largest manufacturing investment in company history.
Surprise: Eli Lilly Is Racing Toward Yet Another Blockbuster
Eli Lilly's once-weekly insulin product just aced phase 3 studies. The company will battle its eternal rival, Novo Nordisk, in this market.
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
Eli Lilly Rises As Study Shows Omvoh Successful in Treating Crohn's Disease
Shares of Eli Lilly (LLY) were on track to close at an all-time high Tuesday as a study showed the pharmaceutical giant's current drug for ulcerative colitis also was successful in treating Crohn's disease.
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Eli Lilly's stock on pace for record close as Crohn's disease trial hits the mark
Eli Lilly & Co. LLY shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn's disease trial and struck a deal to develop new cancer-targeting medicines.
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Eli Lilly's weight loss drugs are driving growth at the pharma company, generating billions of dollars in revenue. This could continue, considering the strong demand for the products.
Aktis to collaborate with Eli Lilly on cancer therapies
Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales.
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat diabetes, improve blood sugar control, and aid in weight loss for adults with type 2 diabetes.
